Treatment of Renal Transplant Recipients With Low Bone Mineral Density: A Randomized Prospective Trial of Alendronate, Alfacalcidol, and Alendronate Combined With Alfacalcidol

Trabulus, Sinan; Altıparmak, Mehmet Rıza; Apaydın, Süheyla; Serdengeçtı, Kamıl; Sariyar, Muzaffer

doi:10.1016/j.transproceed.2007.12.001

Cited by 31 publications

(30 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although gender, baseline BMD, and prednisone doses were similar to our study, their patients were younger and received concurrent calcitriol 0.5 g daily. Alendronate also prevents bone loss immediately after kidney transplantation (30) and improves BMD in long-term kidney transplant recipients (31,32).…”

Section: Discussionmentioning

confidence: 99%

Zoledronic AcidVersusAlendronate for the Prevention of Bone Loss after Heart or Liver Transplantation

Shane

Cohen

Stein

et al. 2012

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Zoledronic AcidVersusAlendronate for the Prevention of Bone Loss after Heart or Liver Transplantation

Shane

Cohen

Stein

et al. 2012

The Journal of Clinical Endocrinology &Amp; Metabolism

View full text Add to dashboard Cite

show abstract

“…We showed that parenteral pamidronate, a second-generation aminobisphosphonate, preserved BMD but was associated with development of adynamic bone disease. 3 Although there have been several prospective studies reporting the effects of parenteral 4,5 and oral bisphosphonates [6][7][8][9] on BMD, there are few studies in renal transplant patients using risedronate, a commonly used third-generation aminobisphosphonate, and its effect on BMD and biochemical measures. 10,11 There are no studies of serial histomorphometry in renal transplant recipients using risedronate.…”

mentioning

confidence: 99%

Effect of Risedronate on Bone in Renal Transplant Recipients

Coco¹,

Pullman²,

Cohen

et al. 2012

Journal of the American Society of Nephrology

View full text Add to dashboard Cite

Bisphosphonates may prevent or treat the bone loss promoted by the immunosuppressive regimens used in renal transplantation. Risedronate is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on the bone health of renal transplant recipients. We randomly assigned 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. We obtained bone biopsies at the time of renal transplant and after 12 months of protocol treatment. Treatment with risedronate did not affect bone mineral density (BMD) in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate did associate with increased osteoid volume and trabecular thickness in male participants, however. There was no evidence for the development of adynamic bone disease. In summary, further study is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommended in renal transplant recipients.

show abstract

“…In a randomized trial that compared alendronate and alfacalcidiol plus alendronate for 1 year of long-term kidney transplant recipients, BMD improved at the LS and FN in both groups. The increase was only significant in the combination alendronatee alfacalcidiol group, however, likely because of inadequate power in this small study [90].…”

Section: Vitamin D and Organ Transplantationmentioning

confidence: 65%